All Oncology News

The implementation and subsequent optimization of a health information technology module within the electronic health record has allowed clinicians across a diverse health care system to identify barriers to improve discrete capture of cancer staging and design solutions to address them.

Alisertib as monotherapy and in combination with fulvestrant stands at the forefront of the clinical investigation of selective AURKA pathway inhibition in patients with endocrine-resistant advanced breast cancer, according to Tufia C. Haddad, MD.

Utilizing obinutuzumab to enhance B-cell depletion significantly reduced the need for corticosteroids and increased relapse-free survival in patients with steroid-requiring chronic graft-vs-host disease undergoing well-matched hematopoietic stem cell transplant.

The National Comprehensive Cancer Network has updated its Clinical Practice Guidelines for Non–Small Cell Lung Cancer for 2024 to include 2 new category 1 recommendations for amivantamab alongside chemotherapy in patients with treatment-naive, EGFR-mutated advanced NSCLC.

Bupathi highlights key points that were presented at an OncLive Institutional Perspectives in Cancer, including implications of the EV-302 trial findings; data updates from the phase 1/2 ICRA trial; and future directions for urothelial cancer.

The FDA has granted breakthrough therapy designation to the HER2-targeted antibody-drug conjugate BNT323/DB-1303 for use as a potential therapeutic option in patients with advanced endometrial cancer who have progressed on or after treatment with immune checkpoint inhibitors.

New research led by a UC Davis Comprehensive Cancer Center clinical scientist shows blood tests used to hunt for cancer DNA may help detect cancers faster and guide the use of targeted therapies.

A supplemental biologics license application and new drug application seeking the approval of amivantamab plus lazertinib as frontline therapy for the treatment of patients with locally advanced or metastatic NSCLC with EGFR mutations have been submitted to the FDA.

The transmembrane protein B7-H4 has emerged as an interesting therapeutic target in multiple solid tumors, with investigators mostly focusing on the development of antibody-drug conjugates aimed at the pathway.

The presence of ESR1 coabnormalities, including TP53 and PIK3CA mutations, and CCND1 and FGFR1 amplification, did not demonstrate a negative impact on the efficacy with lasofoxifene and abemaciclib in patients with estrogen receptor–positive, ESR1-mutant metastatic breast cancer.

The European Commission has approved new indications for pembrolizumab in combination with chemotherapy in select patients with gastric or gastroesophageal adenocarcinoma and select patients with biliary tract cancer.

Quality of life and adverse effects are key components most patients with estrogen receptor–positive, HER2-negative metastatic breast cancer weigh when choosing an anticancer therapy, according to patient-reported results of an ESR1 QUAlity of Life Survey 3 survey.

Paolo Ghia, MD, PhD, describes the various cohorts of the SEQUOIA study, expands on outcomes from a biomarker subgroup analysis with zanubrutinib vs bendamustine plus rituximab, and more.

The Allegheny Health Network Cancer Institute announced today that it has established one of the region’s first clinics dedicated to precision cancer medicine and has appointed nationally recognized medical oncologist Ariel Lopez-Chavez, MD, MS, to serve as director of the new clinic.

Tucatinib, which inhibits phosphorylation of HER2/3 resulting in inhibition of downstream MAPK and AKT signaling and cell proliferation, has shown promise for patients with brain metastases as the small molecule inhibitor of HER2 can cross the blood-brain barrier.

Treatment with 177Lu-PNT2002 resulted in a significant improvement in radiographic progression-free survival vs abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer whose disease had progressed on an androgen receptor pathway inhibitor.

Dostarlimab plus carboplatin and paclitaxel, followed by maintenance dostarlimab and niraparib, significantly improved PFS vs placebo plus chemotherapy followed by placebo in patients with primary advanced or recurrent endometrial cancer, according to data from the phase 3 RUBY trial.

Alan Tan, MD, discusses how utilizing circulating tumor DNA may provide valuable insight into when to escalate vs de-escalate treatment for patients with renal cell carcinoma.

Jennifer R. Brown, MD, PhD, discusses the clinical implications of the ALPINE study and highlights a subgroup analysis of acquired mutations in patients with chronic lymphocytic leukemia, demonstrating which mutations were associated with resistance to covalent BTK inhibitors.

Jaime R. Merchán, MD, spotlights case studies of patients with rare non-ccRCC histologies, discussing their clinical presentation, recent data on immunotherapy and targeted treatment options for the management of these disease subtypes, and patient outcomes on these therapies.

The combination regimen comprised of acalabrutinib, venetoclax, and obinutuzumab proved to be safe and feasible and to elicit responses in patients with high-risk, relapsed or refractory mantle cell lymphoma.

Allina Health Cancer Institute is collaborating with St. Paul-based Astrin Biosciences for a first-of-its-kind clinical trial using artificial intelligence and a simple blood draw to revolutionize how cancer is diagnosed and treated.

Relmacabtagene autoleucel continued to induce responses with acceptable tolerability in Chinese patients with relapsed or refractory mantle cell lymphoma.

The oral selective PIM1 kinase inhibitor TP-3654 appeared to be well tolerated and to show early signals of spleen volume reduction, symptom improvement, and correlating cytokine reductions in patients with relapsed or refractory myelofibrosis, according to preliminary data.

Maria Hafez, MD, spotlights the KATHERINE trial in HER2-positive breast cancer, expanding on the respective toxicity profiles of T-DM1 and trastuzumab that were identified in an exploratory safety analysis of the trial; updated outcomes with T-DM1 in those with residual invasive disease after neoadjuvant treatment and surgery; and more.

Treatment with SD-101 distributed via pressure-enabled drug delivery with immune checkpoint inhibition was tolerated and resulted in the depletion of Tregs, M-MDSCs, and M2 macrophages in liver metastases in patients with uveal melanoma.

Kathleen N. Moore, MD, MS, expands on the importance of continuing to investigate PARP inhibitors in ovarian cancer and highlights key updates to have come out of the 2023 ESMO Congress

Oliver Sartor, MD, discusses the significance of the data with lutetium Lu 177 vipivotide tetraxetan in the open-label, multicenter randomized study, highlights potential next steps with this approach, and expands on unique adverse effects to be aware of when treating patients with this drug.

The FDA has issued a complete response letter to the biologic license application seeking the approval of cosibelimab for use in patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not eligible for curative surgery or radiation.

Diagnosing early-stage lung cancer with low-dose computed tomography screening drastically improves the survival rate of cancer patients over a 20-year period, according to a large-scale international study being presented by Mount Sinai researchers at the annual meeting of the Radiological Society of North America.